IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Average PT from Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has been assigned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $53.67.

Several research analysts have issued reports on IDYA shares. Lifesci Capital upgraded shares of IDEAYA Biosciences to a “strong-buy” rating in a research report on Monday, July 29th. Cantor Fitzgerald started coverage on shares of IDEAYA Biosciences in a research report on Tuesday, October 15th. They issued an “overweight” rating on the stock. JPMorgan Chase & Co. decreased their price target on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Leerink Partnrs cut shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Finally, Wedbush reiterated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Monday, November 4th.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of institutional investors have recently modified their holdings of IDYA. Allworth Financial LP boosted its stake in shares of IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 800 shares during the period. Covestor Ltd boosted its stake in shares of IDEAYA Biosciences by 23,050.0% during the 3rd quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after buying an additional 922 shares during the period. Quest Partners LLC acquired a new stake in shares of IDEAYA Biosciences during the 2nd quarter valued at $41,000. US Bancorp DE lifted its stake in shares of IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after purchasing an additional 689 shares during the last quarter. Finally, Comerica Bank lifted its stake in shares of IDEAYA Biosciences by 723.5% in the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after purchasing an additional 1,324 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $26.79 on Thursday. IDEAYA Biosciences has a 12 month low of $25.20 and a 12 month high of $47.74. The firm has a market capitalization of $2.32 billion, a PE ratio of -11.50 and a beta of 0.86. The company’s 50 day simple moving average is $30.39 and its 200 day simple moving average is $35.78.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter last year, the business posted ($0.46) earnings per share. Sell-side analysts anticipate that IDEAYA Biosciences will post -2.46 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.